Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

NCT07348965 is registered in ClinicalTrials.gov with Guangzhou University of Traditional Chinese Medicine as lead sponsor.

NCT NCT07348965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Lead sponsor
Guangzhou University of Traditional Chinese Medicine
Phase
Not applicable
Overall status
Recruiting
Start date
March 1, 2026
Completion date
December 31, 2028
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, furmonertinib, leptomeningeal metastasis, nsclc (advanced non-small cell lung cancer)